Discontinuation of second- versus first-line disease-modifying treatment in middle-aged patients with multiple sclerosis

Recurrence of disease activity after fingolimod discontinuation in older patients previously stable on treatment

(2021) Vasiliki Pantazou et al.   Multiple Sclerosis and Related Disorders

Discontinuation of disease-modifying treatments for multiple sclerosis in patients aged over 50 with disease Inactivity

(2020) Anne-Laure Kaminsky et al.   JOURNAL OF NEUROLOGY

Decreasing impact of late relapses on disability worsening in secondary progressive multiple sclerosis

(2019) Kevin Ahrweiller et al.   Multiple Sclerosis Journal

Infection Risks Among Patients With Multiple Sclerosis Treated With Fingolimod, Natalizumab, Rituximab, and Injectable Therapies

(2019) Gustavo Luna et al.   JAMA Neurology

Discontinuation of disease-modifying therapy for patients with relapsing-remitting multiple sclerosis: Effect on clinical and MRI outcomes

(2019) Hajime Yano et al.   Multiple Sclerosis and Related Disorders

Interrupting rituximab treatment in relapsing-remitting multiple sclerosis; no evidence of rebound disease activity

(2019) Alexander Juto et al.   Multiple Sclerosis and Related Disorders

Clinical activity after fingolimod cessation: disease reactivation or rebound?

(2018) J. Frau et al.   EUROPEAN JOURNAL OF NEUROLOGY

Predictors of relapse and disability progression in MS patients who discontinue disease-modifying therapy

(2018) Ilya Kister et al.   JOURNAL OF THE NEUROLOGICAL SCIENCES

Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria

(2018) Alan J Thompson et al.   LANCET NEUROLOGY

Discontinuation of disease-modifying therapy in patients with multiple sclerosis over age 60

(2018) Le H Hua et al.   Multiple Sclerosis Journal

ECTRIMS/EAN Guideline on the pharmacological treatment of people with multiple sclerosis

(2018) Xavier Montalban et al.   Multiple Sclerosis Journal

Discontinuation of disease-modifying therapy in patients with multiple sclerosis over age 60

(2018) Le H Hua et al.   Multiple Sclerosis Journal

ECTRIMS/EAN Guideline on the pharmacological treatment of people with multiple sclerosis

(2018) Xavier Montalban et al.   Multiple Sclerosis Journal

Discontinuation of disease modifying treatments in middle aged multiple sclerosis patients. First line drugs vs natalizumab

(2017) Jan Fagius et al.   Multiple Sclerosis and Related Disorders

Meta-analysis of the Age-Dependent Efficacy of Multiple Sclerosis Treatments

(2017) Ann Marie Weideman et al.   Frontiers in Neurology

Rituximab versus fingolimod after natalizumab in multiple sclerosis patients

(2016) Peter Alping et al.   ANNALS OF NEUROLOGY

Can we stop immunomodulatory treatments in secondary progressive multiple sclerosis?

(2016) J. Bonenfant et al.   EUROPEAN JOURNAL OF NEUROLOGY

Discontinuing disease-modifying therapy in MS after a prolonged relapse-free period: a propensity score-matched study

(2016) Ilya Kister et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY

Discontinuation of disease-modifying therapies in multiple sclerosis – Clinical outcome and prognostic factors

(2016) Gabriel Bsteh et al.   Multiple Sclerosis Journal

Rebound Syndrome in Patients With Multiple Sclerosis After Cessation of Fingolimod Treatment

(2016) Stacy Ellen Hatcher et al.   JAMA Neurology

Discontinuation of disease-modifying therapies in multiple sclerosis – Clinical outcome and prognostic factors

(2016) Gabriel Bsteh et al.   Multiple Sclerosis Journal

MS disease activity in RESTORE: A randomized 24-week natalizumab treatment interruption study

(2014) R. J. Fox et al.   NEUROLOGY

Risk stratification for progressive multifocal leukoencephalopathy in patients treated with natalizumab

(2012) Per Soelberg Sørensen et al.   Multiple Sclerosis Journal

Natalizumab and drug holiday in clinical practice: An observational study in very active relapsing remitting Multiple Sclerosis patients

(2011) A. Kerbrat et al.   JOURNAL OF THE NEUROLOGICAL SCIENCES

Disease activity return during natalizumab treatment interruption in patients with multiple sclerosis

(2011) P. W. O'Connor et al.   NEUROLOGY

Natalizumab drug holiday in multiple sclerosis: Poorly Tolerated

(2010) Joep Killestein et al.   ANNALS OF NEUROLOGY

Relapses in multiple sclerosis are age- and time-dependent

(2008) H Tremlett et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY